XBIT - XBiotech Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.29 (+3.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.12
Bid0.00 x 1100
Ask0.00 x 2200
Day's Range9.12 - 9.56
52 Week Range2.13 - 11.74
Avg. Volume183,879
Market Cap339.208M
Beta (3Y Monthly)-0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • How you should trade the biotech ETFs
    CNBC Videos2 months ago

    How you should trade the biotech ETFs

    Ben Johnson of Morningstar and Dave Nadig of ETF.com join 'ETF Edge' to discuss how they're playing biotech ETFs.

  • S&P has best two-month start to year since 1991
    CNBC Videos2 months ago

    S&P has best two-month start to year since 1991

    Jenny Harrington, CEO and portfolio manager at Gilman Hill Asset Management, and Rob Sechan, UBS Private Wealth Management, join 'Fast Money Halftime Report' to discuss what needs to happen to get the market to continue upwards.

  • GlobeNewswire2 months ago

    Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

    XBiotech (XBIT) announced today that breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab, are being presented tomorrow at a late-breaking oral presentation during the annual meeting of the American Academy of Dermatology (AAD) being held  in Washington, DC. The presentation titled, “Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)” will take place on Saturday, March 2 at 1:10pmET in Ballroom A and will be presented by international dermatology expert, and lead researcher in the development of approved therapies for atopic dermatitis, Eric Simpson, M.D, M.C.R. Professor of Dermatology at Oregon Health & Science University, School of Medicine.

  • You Should Be Selling XBiotech Stock After the Huge Gains
    InvestorPlace2 months ago

    You Should Be Selling XBiotech Stock After the Huge Gains

    Two weeks ago, XBiotech (NASDAQ:XBIT) announced positive results from a small Phase 2 trial. It tested its antibody bermekimab for an uncommon inflammatory skin disorder called hidradenitis suppurativa "HS." Since the positive results, XBIT stock has been flying.Source: Shutterstock In fact, XBiotech stock is up from around $5 at the start of the year to $10. Traders have grown really enthusiastic, bidding shares up another 15% on Wednesday. This is a stunning turnaround from last September, when the stock plummeted to as low as $2.13 per share. At this time, it makes sense to be cautious about XBIT stock following this huge rally. Reasons For SkepticismWhen evaluating biotech companies, there's one thing that should always make you nervous. When you see a company trying to use the same product for many different conditions, it is often a bad sign. XBiotech falls firmly into that category.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOver the years, XBiotech has tried their proprietary antibody for a dazzling array of clinical conditions. These include, but are not limited to: colon cancer, lung cancer, vascular restenosis, leukemia, diabetes and even ebola. After the big colon cancer effort failed to deliver what shareholders had been hoping for, the company also brought in Dr. Peter Libby to head up the company's efforts to try their antibody for heart disease and stroke. * 10 Monster Growth Stocks to Buy for 2019 and Beyond Given the way science works, if you run enough small trials, you are likely to hit statistical significance at least occasionally purely by luck. Keep trying your therapy in different applications and it will probably show a result, eventually, somewhere. For seasoned biotech investors, however, a company seemingly using their therapy as a cure-all is usually a clear sign to avoid the stock. Past XBiotech Data IssuesXBiotech has run into numerous situations which raise doubt during its short life as a public company. For one, it seems to use promotional language on many occasions. For example, in its initial IPO prospectus, the company suggested that in a trial for the pyoderma gangrenosum clinical condition: "findings in several patients suggest improved wound healing."The SEC, however, had questions about this statement, forcing XBiotech to offer up a rather less exciting version of the story. XBiotech replied to the SEC that only two patients received the full treatment. They ceded the point that because "the Company does not have sufficient patients numbers at this point, any data results could possibly be misleading to investors."That wasn't XBiotech's only brush with potentially misleading investors. In their much-anticipated colorectal cancer trials, XBiotech again presented what seemed like promising data. However, this was based on what several observers deemed flawed trial design and an odd choice of clinical endpoints. In the end, XBiotech's cancer data reportedly fell apart under scrutiny. Will Things Turn Out Better Now?XBiotech has pivoted from cancer to skin conditions with its same clinical therapy. Again, it's something to note when a company thinks one product can cure so many diseases. However, the company did report what seems like promising results in several trials for dermatological conditions. Some doctors and observers have lauded the data as "promising" and "stellar."Of course, one must use critical thinking. The latest trial, the one that seems to have started the huge run in XBIT stock, only involved 42 patients. It also is just a Phase 2 trial, which is not designed to garner FDA approval. The majority of drug candidates that pass Phase 2 trials fall apart in Phase 3 when more rigorous trial designs come into play.Many microcap biotech companies can show promising results in Phase 2, but struggle to deliver the goods in much larger and more conclusive Phase 3 trials. Given XBiotech's past history with this same compound in other conditions, it's best to be cautious. XBIT Stock VerdictI'm not an investor in many clinical-stage biotech companies, and that certainly applies to XBIT stock. As it is, most biotech companies without a commercialized product fail, and many of those have more promising stories than XBiotech.It's possible that this compound works in skin conditions despite not working previously in cancers, diabetes and a host of other conditions. But looking at the history of biotech development, the odds are pretty long.As for the stock's recent run, almost all commentary on social media relates to momentum and technical analysis. It seems like most people driving the stock up now are short-term traders. And that's fine. But don't take the recent price action as a sign of any special or inside knowledge about upcoming fundamental developments from XBiotech.And, unfortunately for shareholders, once momentum stops, it tends to reverse pretty quickly. When the people who own a stock are there for technical and momentum reasons, they tend to bail as soon as the price starts declining. If traders don't understand or care about a company's fundamental story, they won't stick around for long. All that is to say that XBIT stock will be vulnerable to a large decline in coming weeks.What would stop the current enthusiasm for Xbiotech? A market correction generally would probably cause shares to decline. There is also the possibility that it will want to raise money while the share price is high.That said, and I will give XBiotech credit here, they still had $21 million in cash as of last quarter and are only burning about $4 million per quarter in operating costs. That suggests they can make it through 2019 without raising more money.Still, that's hardly enough reason to hold onto XBIT stock after such a huge run-up.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post You Should Be Selling XBiotech Stock After the Huge Gains appeared first on InvestorPlace.

  • ACCESSWIRE2 months ago

    These 4 Biotech Stocks Are Leading The Industry

    Premier Health Group (PHGRF) (PHGI), Neon Therapeutics Inc (NTGN), Bionano Genomics Inc (BNGO), and XBiotech Inc (XBIT) represent four biotech companies working to champion new treatments for consumers in the space. The Company has magnetized investors looking for opportunities in the biotech sector by strategically investing in products and services that demonstrate Premier's dedication to the industry, as well to patients simply looking for a means of feeling better. Premier Health Group (PHGRF) (PHGI) announced towards the end of last month that, further to itsnew release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire3 months ago

    Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting

    XBiotech (XBIT) announced today that findings from its open label, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) will be presented at the “Late-Breaking Research: Clinical Trials” forum at the American Academy of Dermatology (AAD) Annual Meeting being held March 1-5, 2019 in Washington, D.C. The oral presentation titled, “Bermekimab is a Rapid and Effective Treatment for Atopic Dermatitis (AD)”, will be delivered by international expert and advisor for XBiotech, Eric Simpson, M.D., M.C.R., Professor of Dermatology at Oregon Health & Science University School of Medicine, during the afternoon session on March 2nd, 2019.

  • GlobeNewswire3 months ago

    Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting

    AUSTIN, Texas, Jan. 28, 2019 -- XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for.

  • GlobeNewswire3 months ago

    Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain

    XBiotech (XBIT) announced today the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa (HS).  Primary and key secondary endpoints were met in this study with significant, differentiating findings.  The Company previously published data from its double-blind placebo controlled study in HS using bi-weekly, intravenous infusions of bermekimab in which safety and primary efficacy endpoints were met.

  • GlobeNewswire4 months ago

    XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study

    The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody,  in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these symptoms stabilized or improved with treatment.

  • GlobeNewswire4 months ago

    XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

    XBiotech (XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints.

  • GlobeNewswire5 months ago

    XBiotech Announces Successful Completion of GMP Audit

    XBiotech Inc. (XBIT) today announced a successful GMP (Good Manufacturing Practices) audit by Eurofins Amatsigroup. The audit was conducted in connection with XBiotech’s distribution in Europe of its US-manufactured biological drug product. XBiotech manufactures bermekimab at its campus facility in Austin, Texas and regularly ships the drug to clinics in various countries in the European Union and the United Kingdom.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    XBiotech Highlights Third Quarter Developments for 2018

    XBiotech Inc. (XBIT) today provided an update on recent company developments in its third quarter Form 10-Q filing with the SEC. The Company reports that it continues to make important progress in its clinical and pre-clinical programs in addition to other corporate initiatives. In April 2018, XBiotech announced the launch of a Phase 2, open label clinical trial to evaluate the Company’s True Human™ monoclonal antibody, bermekimab, in patients with moderate to severe Atopic Dermatitis (AD).

  • GlobeNewswire9 months ago

    XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa

      AUSTIN, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical study evaluating ...